My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

5.805 -0.055 (-0.94%)
Streaming Delayed Price Updated: 2:10 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
41 42 Next >
WHO Wants Climate Change Efforts to Prioritize Mental Health
Via Investor Brand Network
Topics Climate Change
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, traders! We're starting off the week with a dive into the biggest pre-market stock movers for Monday morning! 
Via InvestorPlace
Cybin Moves Forward With Phase 1/2a Clinical Trial For Treatment Of Major Depressive Disorder
Cybin Inc. 
Via Benzinga
Psychedelic Stock Gainers And Losers From June 10, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 6.16% at $0.67 
Via Benzinga
Elon Musk Says Psychedelics Should Be Seriously Considered For Therapeutic Uses, Leading Chorus Of Celeb Support
Elon Musk, the Tesla multi-billionaire investor and owner of the largest portion of Twitter (NYSE: TWTR) shares has been discus 
Via Benzinga
Four Key Takeaways from the Catalyst Summit in Canada
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Awarded Board Approval for CYB003 Phase 1/2a Clinical Trial
Via Investor Brand Network
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, investors! With another day starting comes another breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 12.55% at $0.13 
Via Benzinga
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
New Study Suggests That MDMA May Decrease Fear, Boost PTSD Treatment
Via Investor Brand Network
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 7.70% at $0.78 
Via Benzinga
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs. 
Via Benzinga
Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
Cybin Inc. (NEO:CYBN) (NYSE American: CYBE) announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”)... 
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 9.47% at $0.72 
Via Benzinga
New Research Finds That Individuals Prefer Guide with Personal Psilocybin Experience
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Acquisition of Entheon Biomedical’s DMT Clinical Study
Via Investor Brand Network
Cybin Acquires DMT Clinical Study from Entheon Biomedical
From Cybin Inc.
Via Business Wire
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.55% at $0.36 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Adelia Has Reached Milestone Achievements
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievements
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From June 3, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.88% at $0.35 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Spotlighted in “Frontiers in Psychology” Article
Via Investor Brand Network
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
From Cybin Inc.
Via Business Wire
Cybin, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 9.50% at $0.75 
Via Benzinga
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host Webinar Delving into Psychedelics Landscape, Current and Emerging Therapeutics
Via Investor Brand Network
Cybin to Host Key Opinion Leader Webinar on June 9, 2022
From Cybin Inc.
Via Business Wire
ATAI Life Sciences, Intelgenx Technologies Among Top Psychedelic Movers Of Today
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 7.05% at $0.91 
Via Benzinga
Oregon Adopts First Installment of Psilocybin Rules
Via Investor Brand Network
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.